Literature DB >> 31981290

Refractory palmoplantar pustulosis succesfully treated with apremilast.

Raquel Carrascosa de Lome1, Elena Conde Montero1, Pablo de la Cueva Dobao1.   

Abstract

Palmoplantar pustulosis is a chronic inflammatory disease which characterized by a eruption of sterile pustules on the palms and soles. Apremilast is an oral phosphodiesterase-4 inhibitor which is approved for the treatment of chronic plaque psoriasis and psoriatic arthritis. However, no clinical trial has been performed to confirm the efficacy of apremilast for palmoplantar pustulosis yet. Moreover, there are very few cases of this disease treated with apremilast. Herein, we describe a case of a refractory palmoplantar pustulosis succesfully treated with apremilast.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  inflammatory disorders; psoriasis; therapy-systemic

Mesh:

Substances:

Year:  2020        PMID: 31981290     DOI: 10.1111/dth.13230

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  1 in total

1.  [Apremilast in the treatment of palmoplantar pustulosis : A case series].

Authors:  Nina Frischhut; Gudrun Ratzinger
Journal:  Hautarzt       Date:  2021-03       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.